Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 5/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.57 |
| ▸ | WNT3A | P56704 | 4/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781840 | 1.00 | KDM4E (0.67) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL31148407 | 0.84 | KDM4E (0.66) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL7668372 | 0.84 | KDM4E (0.66) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL29444537 | 0.82 | FLT3 (0.65) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL5353834 | 0.82 | FLT3 (0.65) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL42245 | 0.82 | FLT3 (0.65) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL591861 | 0.81 | KDM4E (0.62) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL82761 | 0.81 | KDM4E (0.62) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL12441826 | 0.81 | KDM4E (0.57) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL967165 | 0.81 | KDM4E (0.62) | KDM4EYTHDC1STAT3HIF1AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164979-A | Azaindole PI3K delta inhibitor, preparation method and application thereof | 浙江大学 | 2024-06-11 | — | — | CN | claimed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12479836-B2 | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient | LG CHEM, LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-3528813-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEV 1 INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118164979-A | Azaindole PI3K delta inhibitor, preparation method and application thereof | 浙江大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-1261607-A1 | 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002088133-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-2,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6462039-B1 | SUCH AS O-(2-((5,6-DIHYDRO-(1,4,2)DIOXAZIN-3-YL)-METHOXY-IMINOMETHYL)-BENZYL)1-(1 -METHYL-1H-INDAZOL-3-YL)ETHANONEOXIME; WELL TOLERATED BY PLANTS; CONTROLLING PLANT DISEASES BY TREATMENT OF AERIAL PARTS, SEEDS OR SOIL | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| WO-2001064674-A1 | 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1077948-A1 | NOVEL 1,2,5-TRISUBSTITUTED 1,2-DIHYDRO-INDAZOL-3-ONES WITH ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY, IMMUNO-MODULATING AND NEURO-PROTECTIVE EFFECT, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2001-02-28 | — | — | EP | disclosed |
| EP-1071682-A2 | FUNGICIDAL BENZOHETEROCYCLYLOXIME | BAYER AG (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6180637-B1 | THERAPY FOR PARKINSON, ALZHEIMER DISEASE | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2001-01-30 | — | — | US | disclosed |
| WO-1999058504-A9 | NOVEL 1,2,5-TRISUBSTITUTED 1,2-DIHYDRO-INDAZOL-3-ONES WITH ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY, IMMUNO-MODULATING AND NEURO-PROTECTIVE EFFECT, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT | DRESDEN ARZNEIMITTEL (DE) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999058504-A1 | NOVEL 1,2,5-TRISUBSTITUTED 1,2-DIHYDRO-INDAZOL-3-ONES WITH ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY, IMMUNO-MODULATING AND NEURO-PROTECTIVE EFFECT, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999046263-A2 | FUNGICIDAL BENZOHETEROCYCLYLOXIME | BAYER AKTIENGESELLSCHAFT (DE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479836-B2 | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient | S1PR1, S1PR2, S1PR4 | KDM4E 3159/4885YTHDC1 2524/4885STAT3 2445/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | KDM4E 3230/4885YTHDC1 3940/4885STAT3 3874/4885 |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | KDM4E 2710/4885YTHDC1 1593/4885STAT3 4259/4885 |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | KDM4E 2710/4885YTHDC1 1593/4885STAT3 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.